Eisai Co., Ltd. continues to stand behind the U.S. Food and Drug Administration (FDA) approval of ADUHELM (aducanumab-avwa) and the data from clinical studies described in the label. Eisai has been engaged in providing medical professionals in clinical practices with information to help educate about the medication's label. Currently, we are focused on promoting ADUHELM at medical institutions and improving drug access for patients, including increasing the number of infusion centers capable of administering ADUHELM. Eisai remains committed to supporting access to ADUHELM for all appropriate patients.
Public Relations Department
Eisai Co., Ltd.
(C) 2021 Electronic News Publishing, source ENP Newswire